A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Gilteritinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 12 Jun 2017 Planned End Date changed from 27 May 2017 to 1 Jun 2017.
- 12 Jun 2017 Status changed from recruiting to active, no longer recruiting.